Atomo FY26 slides: 41% revenue growth, new CEO named
Atomo Diagnostics reported a 41% increase in revenue for fiscal 2026, reaching A$5.3 million, while its underlying EBITDA loss narrowed by 39% to A$2.06 million. The company's shares closed near A$0.02, reflecting cautious market sentiment despite the improvements. Dr. Cheri Walker was appointed as Interim CEO, replacing founder John Kelly after 15 years of leadership.
The company is transitioning to sustainable revenue growth with a growing product pipeline, focusing on point-of-care diagnostic products for global markets.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
